Endothelial Dysfunction in Ischemic Heart Disease
In the catheterization laboratory, acetylcholine (ACh) is used as a practical stimulus to assess endothelial dysfunction in humans 13 because it causes muscarinic-receptor mediated, endothelium-dependent release of NO, which in turn induces vasodilatation. 14 Therefore, intracoronary ACh challenge is ideal for assessing the functional integrity of the endothelium in patients, but because of the different mechanisms of endothelial stimulation, the endothelial effects of the different risk factors vary. Acetylcholinereceptor-mediated vasodilation is impaired in the early stages of the disease, whereas flow-dependent dilation is blunted in advanced stages. 15 Therefore, ACh-receptormediated testing provides the earliest evidence of endothelial dysfunction in the human coronary circulation. On the other hand, a caveat of this testing is that ACh exerts a direct vasoconstrictive effects on human vascular smooth muscle cells. 16, 17 Furthermore, large epicardial and microvascular responses to ACh correlate closely with the response to phys-iologic stimuli such as exercise, 18, 19 tachycardia, 20 and mental stress, 21, 22 so ACh-receptor-mediated responses are likely to be a clinically useful and relevant test for the presence of abnormal regulation of coronary vascular tone and coronary blood flow in response to physiologic stimuli.
The contributions of NO in endothelium-dependent vasodilation may differ between large epicardial vessels and microvessels. Pretreatment with the NO synthase inhibitor L-N-monomethyl-L-arginine blunts ACh-induced vasodilatation, 14, 23 indicating that ACh-induced endothelial vasodilatation is largely mediated by NO. In contrast, ACHinduced endothelial dilation of the microcirculation seems to be mediated only partly by NO. 14, 23 Many studies demonstrate that endothelial dysfunction and activation is one of the earliest markers in patients with atherogenic risk factors (male gender, 24 aging, 25, 26 hypertension, 27 diabetes mellitus, 28 smoking, 29 family history 30 ) in the absence of angiographic evidence of atherosclerosis. There is a negative correlation between the number of risk factors and the degree of endothelial dysfunction. 24, 31 LDL, especially oxidized LDL, inhibits endothelial function through inhibition of NO activity by downregulation of endothelial NO synthase expression, decreased receptor-mediated release of NO, or inactivation of NO via superoxide anion production. Importantly, improved endothelial function is the clinical marker of atherogenic risk factor modification. For example, endothelial dysfunction is improved by therapy with cholesterol-lowering statins. [32] [33] [34] Large clinical studies have demonstrated that statin treatment reduces the cardiovascular event rate in patients with hypercholesterolemia and those with average blood cholesterol levels. [35] [36] [37] Thus, the beneficial effects of cholesterol-lowering therapy with statin might be attributable to rapid and persistent improvement of endothelial dysfunction and activation. 38 Recently, direct beneficial effects of statins on arterial walls that are independent of the cholesterol-lowering effects have attracted attention. 39, 40 We demonstrated that very short-term treatment with statins (ie, 3 days) that had no effect on serum lipids, improved endothelial function by increasing NO activity in patients. 41, 42 Such shortterm statin therapy decreased plasma concentrations of 8-isoprostane (a reliable marker of oxidative stress) and soluble vascular cell adhesion molecule-1. 42 Because vasoconstriction of large epicardial vessels and small resistance coronary arteries occurs because of endothelial dysfunction in response to physiologic stimuli, [18] [19] [20] [21] endothelial dysfunction of coronary arteries is presumed to contribute to effort-related angina pectoris. In addition, impaired endothelial function of the coronary microcirculation leads to reduced blood flow supply to the myocardium during increased metabolic demand. 19 Therefore, endothelial dysfunction of the coronary microcirculation alone can cause or promote myocardial ischemia, even in the absence of flow-limiting stenosis of the large epicardial arteries. Indeed, endothelial dysfunction of the coronary microcirculation has been demonstrated in patients with microvascular angina pectoris. 43, 44 On the other hand, there is a debate over the role of endothelial dysfunction in the pathogenesis of epicardial coronary artery spasms in patients with vasospastic angina pectoris. 45, 46 Besides contributing to the manifestation of myocardial ischemia, endothelial dysfunction may have a crucial role in acute coronary syndromes, such as unstable angina pectoris or myocardial infarction, 8, 47 which are characterized by plaque rupture or erosion followed by platelet aggregation and local thrombus formation. 47 The endothelium has a crucial role in modulating these events because in the presence of endothelial dysfunction, increased constriction in response to platelet products can trigger plaque rupture. Thus, endothelial dysfunction is likely to contribute causally to the clinical aggravation of acute coronary syndromes and its amelioration is a therapeutic goal that very probably contributes, at least in part, to a reduction of clinical events in the long-term.
Endothelial NO as an Endogenous Anti-Arteriosclerotic Molecule
Endothelium-derived NO is now recognized to be an anti-inflammatory and anti-arteriosclerotic molecule; mice lacking the endothelial-type NO synthase gene exhibit hypertension and enhanced vascular remodeling in response to injury. 48, 49 Deficiency of the endothelial-type NO synthase gene increases atherogenesis in hypercholesterolemic apolipoprotein E-deficient mice and induces distal coronary artery disease, left ventricular dysfunction, and aortic aneurysm/dissection. 50, 51 To investigate the role of NO in the development of postnatal vascular disease, NO synthesis was inhibited pharmacologically by long-term administration of a selective and specific NO synthesis inhibitor (L-arginine analogue, N -nitro-L-arginine methyl ester, L-NAME) to healthy adult rats (Fig 1) and it was found that (1) endothelial NO production was markedly reduced in rats that received L-NAME, but not in those that received D-NAME, an inactive form of L-NAME 52-54 and (2) administration of D-NAME did not cause hypertension or cardiovascular pathologic changes. 55 In the early stages (day 3-7) of long-term NO synthesis inhibition, there aere marked inflammatory (adhesion and infiltration of monocytes) and proliferative (appearance of proliferating cell nuclear antigen-positive cells) changes in the blood vessels, especially the coronary arteries. 55 Simultaneously, there is (1) increases in tissue angiotensin-converting enzyme (ACE) and angiotensin type I receptor, resulting in an increase in AII activity; 53, 54, 56 (2) increased gene and protein expression of chemokines such as MCP-1, 55, 57 and cytokines such as transforming growth factor-(TGF-), tissue factor etc); [58] [59] [60] and (3) increased production of superoxide anions ensuring oxidative stress, and increased activities of transcription factors (NF-B and AP-1). 61, 62 All of these pathophysiologic and pathobiologic changes are probably the result of NO synthesis inhibition, but do not result from nonspecific actions of L-NAME, because (1) normalization of L-NAME-induced hypertension by treatment with hydralazine does not have an effect; 53,54 (2) restoration of NO synthesis by co-administration of L-arginine prevents L-NAME-induced pathologic changes; 55 and (3) administration of D-NAME does not cause hypertension or pathologic changes. 55 In the late stage (week 4-8), structural changes in the cardiovascular system, such as arteriosclerosis (medial thickening and fibrosis), cardiac hypertrophy and fibrosis, renal damage, and stroke, [52] [53] [54] are observed. A considerable proportion of animals died because of arteriosclerosis and its complications. Vascular inflammation in the early stages appears to be essential to the later development of arteriosclerosis because when early vascular inflammation is induced by administration of L-NAME for only 7 days it results in arteriosclerosis. 63 These findings suggest that NO synthesis inhibition actually causes functional and structural vascular abnormalities and support the hypothesis that endothelium-derived NO has a central role in the maintenance of normal function and structure (homeostasis) in the blood vessel wall.
The molecular and cellular mechanisms of vascular lesion formation induced by long-term NO synthesis inhibition have been further investigated and it has been found that ACE inhibition or AII type 1 receptor blockade prevents early vascular inflammation and later arteriosclerosis, 53, 54, 64 indicating that increased local activity of AII has a central role in the development of the pathologic changes (Fig 1) . Anti-oxidant therapy 64, 65 or blockade of NF-B by transfection of a cis-element decoy 66 prevents vascular lesion formation, blockade of MCP-1 partly reduces vascular lesion formation, 67 and blockade of TGF-1 58,68 prevents vascular fibrosis. Taken together, these observations suggest that oxidative stress and subsequent activation of NF-B mediate vascular inflammation through the expression of MCP-1, whereas vascular fibrosis is mediated independently by increased activity of TGF-1. These data could be the basis for an in vivo model of how endothelium-derived NO has anti-inflammatory and anti-arteriosclerotic properties in the vascular endothelium.
Recent clinical studies report that the presence of endothelial dysfunction is a significant predictor of future cardiovascular events. 69, 70 From the clinical point of view, therapies such as statins, ACE inhibitors etc that decrease the progression of arteriosclerosis and its complications, all improve endothelial dysfunction in patients with risk factors. Endothelium-derived NO appears to protect the arteries in humans.
Summary and Perspective for Future Treatment
Arteriosclerosis and atherosclerosis both develop as a result of a healing response to repetitive injury to the arterial wall. Numerous risk factors contribute to the development and progression of arteriosclerosis and atherosclerosis and of these, endothelium-derived NO is the key factor protecting the artery, which in turn prevents the ischemic manifestations of arteriosclerosis. Thus, any therapeutic interventions aimed at increasing NO bioactivity will improve the patient's prognosis and the observed clinical benefits of statins and ACE inhibitors are attributed, at least in part, to improved endothelial NO activity. Therefore, endothelium-derived NO is a clinically relevant therapeutic target for cardiovascular disease.
Gene therapy for vascular disease will be the next clinical challenge. The transfer of the NO synthase gene improves vascular reactivity 71, 72 and reduces atherogenesis in animals. 73 Currently, either modification of the risk factors for arteriosclerosis or palliative intervention aimed at dilating flow-limiting atherosclerotic stenosis is the main therapy for atherosclerotic disease. To advance the medical frontier of 21st century medicine, however, will require the development of novel therapies or drugs that facilitate specific and effective inhibition of the inflammatory processes, differentiation and proliferation of vascular smooth muscle cells, or oxidative stress generating systems. Because restenosis hampers the clinical benefits of coronary intervention, 74 ,75 its prevention is a major clinical challenge that highlights the need for new therapeutic options such as gene therapy. To this end, anti-MCP-1 gene therapy against human restenosis following percutaneous coronary intervention is being attempted. Inflammatory responses to injury, which accelerate the recruitment and activation of monocytes through the activation of chemokines including MCP-1, could be central in restenosis and atherosclerosis and so MCP-1 may be a novel therapeutic target. 76 A new strategy for anti-MCP-1 gene therapy by transfecting an Nterminal deletion mutant of the MCP-1 gene into skeletal muscles has been recently devised. 76 The mutant MCP-1 lacks the N-terminal amino acids 2-8, called 7ND, and acts as a dominant-negative inhibitor of MCP-1. 77 It has been demonstrated that (1) MCP-1 is increased in restenotic and atherosclerotic lesions; (2) blockade of MCP-1 by this strategy suppresses monocyte infiltration/activation at the injured site and markedly inhibited restenotic changes (neointimal hyperplasia) after balloon injury or stenting in animals; 78 and (3) in hypercholesterolemic mice blockade of MCP-1 not only attenuates the development of atherosclerosis, but also limits progression of pre-existing atherosclerotic lesions and improves the lesion composition into a more stable phenotype (containing fewer macrophages and lymphocytes, less lipid, more smooth muscle cells and collagen). 79, 80 Therefore, vascular inflammation mediated by MCP-1-mediated monocyte infiltration and activation may be central to the pathogenesis of restenosis and atherosclerotic vascular disease.
